

## **ASX RELEASE**

### **ADMEDUS INITIATES COLLABORATION ON STEM CELL DELIVERY**

- Admedus to work with leading regenerative stem biology institute to investigate stem cell delivery on ADAPT™ tissue for regenerative repair
- On identifying the most suitable stem cell population, Admedus will undertake separate models of tissue regeneration, including functional remodelling of the heart after myocardial infarct (heart attack)
- These studies are in line with Admedus' strategy to bring a range of ADAPT based products to market

#### **Brisbane, Australia 30 September 2015**

Admedus Limited (ASX: AHZ) has today announced that it will work with the Ear Science Institute Australia (ESIA) using their regenerative cell biology expertise to facilitate the delivery of stem cells on ADAPT™ tissue in both in vitro and in vivo models.

The studies will investigate a range of bone marrow derived mesenchymal stem cells and adipose derived stem cells delivered on a variety of Admedus' ADAPT treated tissues to examine their regenerative capacity.

"These are important studies to further validate the utility of ADAPT tissue as a delivery platform for stem cells and other cellular therapies," said Admedus CEO, Mr Lee Rodne.

"The research using ADAPT tissue and stem cells is part of the Admedus strategy to develop a number of regenerative tissue products based on the ADAPT tissue engineering technology, which produces tissues that limit calcification and are effectively remodelled, making them ideal for a broader range of surgical products."

The studies with ESIA will explore the levels of regeneration, vascularisation and cell differentiation when ADAPT tissue is used with stem cells. Previous data in heart valves has shown a strong level of autologous regeneration and vascularisation around the ADAPT tissue that is facilitated by cells.

“We are excited to work with Admedus on this important project. As a leading research institution, there was a natural synergy between our work in studying regenerative cell biology and Admedus’ interest in using their bio-scaffolds to deliver stem cells. We look forward to continuing to work closely with Admedus in the aim of improving patient outcomes,” said Associate Professor Rodney Dilley, Head of Molecular and Cellular Otolaryngology at ESIA.

Associate Professor Dilley has significant expertise in stem cell biology with published work characterising aspects of their angiogenic potential as well as recognised expertise in the differentiation of stem cells to cardiogenic cells for cardiac tissue engineering.

On identifying the most suitable stem cell population, Admedus will move into a separate larger scale in vivo study of tissue regeneration, including functional remodelling of the heart after myocardial infarct.

Historically ADAPT tissue has shown to be an ideal platform for cellular therapies such as stem cells. The data from these studies will assist Admedus in developing its ADAPT scaffolds as the ideal stem cell delivery platform to improve repair in a wide range of indications, including heart tissue after myocardial infarct.

Follow us:

Twitter: @Admedus

Facebook: [www.facebook.com/pages/Admedus](https://www.facebook.com/pages/Admedus)

**For more information, please contact:**

Dr Julian Chick | Chief Operating Officer | Admedus Limited

Tel: +61 (0)8 9266 0100

**Media:**

Shevaun Cooper | PR Manager | Admedus Limited

Tel: +61 (0) 417 985 599 | Email: [scooper@admedus.com](mailto:scooper@admedus.com)

**Media Europe**

FTI Consulting

Simon Conway / Victoria Foster Mitchell

Tel: +44 (0) 20 3727 1000

[admedus@fticonsulting.com](mailto:admedus@fticonsulting.com)

**About Admedus Limited**

Admedus (ASX: AHZ) is a specialist healthcare company. Our focus is on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow product and service offerings and expanding revenues from our existing, profitable medical sales and distribution business. The company has assets from research & development through clinical development as well as sales, marketing and distribution.

Admedus has commercialised its innovative tissue engineering technology for regenerative medicine in four continents. We also have a major interest in developing the next generation of vaccines with a Brisbane-based research group led by Professor Ian Frazer. The vaccine programmes target disease with significant global potential, such as Herpes and Human Papillomavirus.

Further information on the company can be found on [www.admedus.com](http://www.admedus.com)

### **About Admedus Regen Pty Ltd**

Admedus Regen Pty Ltd started as a research programme in 2001, focusing on tissue engineering and regenerative medicine based around the proprietary ADAPT® Tissue Engineering Process. The lead programme, CardioCel®, is approved in Europe, Asia, Hong Kong, Singapore the US and Canada and is being used in Australia under the Authorised Prescriber Scheme. Admedus Regen is based on the patented ADAPT Tissue Engineering Process as a platform technology to produce implantable tissue scaffolds for use in various soft tissue repair applications and for the production of replacement tissue heart valves. The ADAPT technology is used to process xenograft tissues to produce unique, implantable tissue scaffolds that are compatible with the human body. The technology has a number of advantages over current tissue treatment processes on the market, most notably the reduction of calcification post-implantation, and has the potential to replace many of the products that surgeons currently use for soft tissue repair. ADAPT® is a registered trademark.

### **About Ear Science Institute Australia**

Established in 2001, Ear Science Institute Australia is an independent not-for-profit organisation dedicated to improving ear and hearing outcomes through education and translational, solutions-based research (patient-to-laboratory-to-patient). With robust and dynamic links between researchers and clinicians, we are an active and committed education and training organisation. Our approach is multi-disciplinary in nature, employing skills from diverse fields such as otolaryngology, audiology, engineering, computer science and molecular and cellular sciences. We are uniquely placed to resolve the issues faced by the one in six Australians who live with hearing loss today, and projected to effect one in four by 2050. With our dedicated ear health focus, expert staff and collaborative relationships that span the globe, the services and research conducted at the Ear Science Institute Australia focuses on the

attainment of a cure, prevention through education, and support of those suffering today from not only the physical effects of hearing loss but also the impact it has on their relationships, careers and quality of life.